Research and Markets: Concise Analysis of the Osteoporosis Therapeutics Market - Forecasts to 2022

Research and Markets (http://www.researchandmarkets.com/research/7sbnr6/pharmapoint) has announced the addition of the "Concise Analysis of the Osteoporosis Therapeutics Market - Forecasts to 2022" report to their offering.

Despite its maturity, the osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the gold-standard' bisphosphonates will lose patent protection by end-of-year 2013, flooding the marketplace with less expensive generic versions of these physician-preferred medications. Additionally, Eli Lilly's blockbuster Evista, the only available SERM in the US, will lose patent protection in 2014, flooding the market with yet more affordable generic options.

Also during the forecast period covered by this report, osteoporosis drug development research will lead to the launches of a wave of novel anabolic drugs with greater efficacy and safety, causing a major market shift away from anti-resorptive drugs. The number of companies vying for patient share will shrink by as much as 50%, as established players exit the market or acquire smaller players. Lastly, the aging of the population in developed markets will result in a larger patient pool.

These changes in the osteoporosis market will be reflected in the slow growth during the forecast period, with the market growing from $6 billion to $8 billion in 2011 USD at a CAGR of 3%. The large dip in sales caused by these expiries is offset by six pipeline product launches over the forecast period, with three of these being potential blockbuster drugs.

Reasons to buy

• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of the competition by understanding the changing competitive landscape for Osteoporosis
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of drug performance
• Obtain sales forecast for drugs from 2012-2022 in the US

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

4 Disease Management

5 Competitive Assessment

6 Opportunity and Unmet Need

7 Pipeline Assessment

8 Market Outlook

9 Appendix

For more information visit http://www.researchandmarkets.com/research/7sbnr6/pharmapoint

Research and Markets
Laura Wood, Senior Manager.
[e-mail]
U.S. Fax: [phone]
Fax (outside U.S.): [phone]
Sector: Pharmaceuticals